Evidence map›Paper›PMID 30448882›Full record

ArticleJournal of cancer research and clinical oncology2019

Calpain system protein expression and activity in ovarian cancer.

Siwei Zhang, Suha Deen, Sarah J Storr, Panagiota S Chondrou, Holly Nicholls, Anqi Yao, Ployphailin Rungsakaolert, Stewart G Martin

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. High BMP7 expression is associated with poor prognosis in ovarian cancer.Journal of cellular and molecular medicine · 2023
    Article
  6. The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Expression of Syk and MAP4 proteins in ovarian cancer.Journal of cancer research and clinical oncology · 2019
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Siwei ZhangAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Suha DeenDepartment of Histopathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK.
Sarah J StorrAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Panagiota S ChondrouAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Holly NichollsAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Anqi YaoAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Ployphailin RungsakaolertAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK.
Stewart G MartinAcademic Clinical Oncology, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK. stewart.martin@nottingham.ac.uk.
Nottingham University Hospitals NHS Trust · GBUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExpression of members of the calpain system are associated with clinical outcome of patients with, amongst others, breast and ovarian cancers, with calpain-2 expression in ovarian cancer being implicated in chemo-resistance and survival. This study aimed, using a large patient cohort and in vitro models, to verify its importance and further investigate the role in ovarian cancer chemoresponse.

methodsCalpain-1, calpain-2, calpain-4 and calpastatin expression were evaluated in primary ovarian carcinomas (n = 575) by immunohistochemistry. Protein expression was assessed, via western blotting, in five ovarian cancer cell lines with various sensitivities towards cisplatin/carboplatin. In vitro calpain activity was inhibited by calpeptin treatment to assess changes in platinum sensitivity by proliferation assay, with expression of genes associated with epithelial-mesenchymal transition being examined by RT

resultsThe current study confirmed previous data that high calpain-2 expression is associated with poor overall survival (P = 0.026) and that calpain-1 was not associated with overall survival or progression-free survival. Low expression of calpastatin (P = 0.010) and calpain-4 (P = 0.003) were also associated with adverse survival. Such prognostic associations do not seem to be linked with altered tumour sensitivity towards platinum-based chemotherapy. Interestingly, low calpain-1 expression was more frequent in patients with confined tumours (stage 1) (χ

conclusionsThe conventional calpains and calpastatin have been confirmed to play an important role in ovarian cancer; however, the precise mechanisms whereby they exert effects remain to be elucidated.

Indexed as

Adenocarcinoma, Clear CellAdenocarcinoma, MucinousAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCalcium-Binding ProteinsCalpainCell ProliferationCohort StudiesCystadenocarcinoma, SerousEndometrial NeoplasmsEpithelial-Mesenchymal TransitionFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMiddle AgedBiomarkers, TumorCalcium-Binding ProteinsCalpaincalpastatinCAPN1 protein, humanCAPN2 protein, humanCAPNS1 protein, humanCalpainCalpastatinChemotherapyEpithelial–mesenchymal transitionOvarian cancer

Identifiers

PMID30448882
PMCPMC6373250
OpenAlexW2900599476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.